Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2009 1
2010 1
2014 2
2015 2
2017 2
2018 3
2019 1
2020 1
2021 5
2022 8
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for luciani a. alone
Search for Luciana A. Nalone instead (1 results)
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial.
Féray C, Campion L, Mathurin P, Archambreaud I, Mirabel X, Bronowicki JP, Rio E, Perret C, Mineur L, Oberti F, Touchefeu Y, Gournay J, Regnault H, Edeline J, Rode A, Hillion P, Blanc JF, Khac EN, Azoulay D, Luciani A, Preglisasco AG, Faurel-Paul E, Auble H, Mornex F, Merle P. Féray C, et al. Among authors: luciani a. JHEP Rep. 2023 Jan 29;5(4):100689. doi: 10.1016/j.jhepr.2023.100689. eCollection 2023 Apr. JHEP Rep. 2023. PMID: 36937990 Free PMC article.
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
Petrelli F, Rea CG, Solinas C, Ghidini A, Borgonovo K, Celotti A, Villa A, Luciani A, Lorusso D. Petrelli F, et al. Among authors: luciani a. Cancer Treat Rev. 2023 Jul;118:102571. doi: 10.1016/j.ctrv.2023.102571. Epub 2023 May 11. Cancer Treat Rev. 2023. PMID: 37201444 Review.
Various strategies, including secondary cytoreduction followed by platinum-based CT, carboplatin + pegylated liposomal doxorubicin + bevacizumab, and platinum-based CT with bevacizumab or cediranib, were better than platinum-based doublets alone for PFS. CONCLUSIONS: This …
Various strategies, including secondary cytoreduction followed by platinum-based CT, carboplatin + pegylated liposomal doxorubicin + bevaciz …
Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis.
Petrelli F, Luciani A, Ghidini A, Cherri S, Gamba P, Maddalo M, Bossi P, Zaniboni A. Petrelli F, et al. Among authors: luciani a. Head Neck. 2022 May;44(5):1255-1266. doi: 10.1002/hed.27019. Epub 2022 Mar 3. Head Neck. 2022. PMID: 35238114 Review.
Chemoradiation improved survival in a definitive curative setting compared with radiotherapy alone (HR = 1.42, 95% CI 1.16-1.75; p < 0.01). When adjuvant treatments were compared, standard and de-escalation strategies provided similar OS. ...
Chemoradiation improved survival in a definitive curative setting compared with radiotherapy alone (HR = 1.42, 95% CI 1.16-1.75; p &l …
Different neoadjuvant therapies for locally advanced rectal cancer: A systematic review and network meta-analysis.
Petrelli F, Trevisan F, Tomasello G, De Stefani A, Viti M, Garrone O, Luciani A, Ghidini M. Petrelli F, et al. Among authors: luciani a. Crit Rev Oncol Hematol. 2022 Dec;180:103853. doi: 10.1016/j.critrevonc.2022.103853. Epub 2022 Oct 15. Crit Rev Oncol Hematol. 2022. PMID: 36252747 Review.
The incorporation of further chemotherapy cycles (CT) before or after CTRT (total neoadjuvant therapy) resulted in better outcomes than CTRT alone. Therefore, we performed a network meta-analysis (NMA) to compare the relative efficacy of different neoadjuvant treatments fo …
The incorporation of further chemotherapy cycles (CT) before or after CTRT (total neoadjuvant therapy) resulted in better outcomes than CTRT …
The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis.
Petrelli F, Dottorini L, Di Menna G, Borgonovo K, Parati MC, Rea CG, Ghilardi M, Ghidini A, Luciani A. Petrelli F, et al. Among authors: luciani a. Breast. 2023 Oct;71:138-142. doi: 10.1016/j.breast.2023.05.002. Epub 2023 May 13. Breast. 2023. PMID: 37198053 Free PMC article. Review.
METHODS: We selected only English-language phase II/III randomized controlled trials that compared ET alone with ET with anti-CDK4/6 inhibitors in the treatment of advanced BC, with subgroups reporting the outcomes of elderly patients (usually at least 65 years). ...
METHODS: We selected only English-language phase II/III randomized controlled trials that compared ET alone with ET with anti-CDK4/6 …
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis.
Petrelli F, Ferrara R, Signorelli D, Ghidini A, Proto C, Roudi R, Sabet MN, Facelli S, Garassino MC, Luciani A, Roviello G. Petrelli F, et al. Among authors: luciani a. Immunotherapy. 2021 May;13(7):621-631. doi: 10.2217/imt-2020-0224. Epub 2021 Mar 29. Immunotherapy. 2021. PMID: 33775103
In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to chemotherapy may improve both OS compared with chemotherapy alone. Lay abstract We provide a meta-analysis of randomized controlled trials in first-line studies where imm …
In this meta-analysis, there is moderate evidence that the addition of immune checkpoint inhibitors to chemotherapy may improve both OS comp …
Ribociclib in the Treatment of Hormone-Receptor Positive/HER2-Negative Advanced and Early Breast Cancer: Overview of Clinical Data and Patients Selection.
Parati MC, Pedersini R, Perego G, Reduzzi R, Savio T, Cabiddu M, Borgonovo K, Ghilardi M, Luciani A, Petrelli F. Parati MC, et al. Among authors: luciani a. Breast Cancer (Dove Med Press). 2022 Apr 12;14:101-111. doi: 10.2147/BCTT.S341857. eCollection 2022. Breast Cancer (Dove Med Press). 2022. PMID: 35440873 Free PMC article. Review.
Among pre- and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), combinations of an aromatase inhibitor (AI) or fulvestrant with a CDK 4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) have demonstrated improved progression-free survival (PFS) an …
Among pre- and postmenopausal women with hormone receptor-positive (HR+) breast cancer (BC), combinations of an aromatase inhibitor (AI) or …
Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
Parisi A, Ghidini M, Giampieri R, Tomasello G, Luciani A, Ferri C, Berardi R, Petrelli F. Parisi A, et al. Among authors: luciani a. Clin Colorectal Cancer. 2022 Sep;21(3):e162-e170. doi: 10.1016/j.clcc.2021.12.005. Epub 2022 Jan 31. Clin Colorectal Cancer. 2022. PMID: 35184993 Review.

Within patients evaluable for OS, CT + anti-EGFR combinations continued until disease progression were able to decrease the risk of death by 32% (HR 0.68; 95% CI 0.56-0.84; P < .01) and the risk of progression by 25% (HR 0.75; 95% CI 0.65-0.85; P < .01) over no maintenance

…
Within patients evaluable for OS, CT + anti-EGFR combinations continued until disease progression were able to decrease the risk of death by …
Risk of Infection with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C. Petrelli F, et al. Among authors: luciani a. Target Oncol. 2021 Sep;16(5):553-568. doi: 10.1007/s11523-021-00824-3. Epub 2021 Jul 5. Target Oncol. 2021. PMID: 34224061 Free PMC article.
PATIENTS AND METHODS: The Cochrane Library, EMBASE, and Pubmed databases were searched up to 1 December 2020. Randomized trials comparing any ICI alone, with chemotherapy (CT), or with other agents versus placebo, CT, or other agents were included. ...ICIs were associated …
PATIENTS AND METHODS: The Cochrane Library, EMBASE, and Pubmed databases were searched up to 1 December 2020. Randomized trials comparing an …
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis.
Petrelli F, Bertaglia V, Parati MC, Borgonovo K, De Silva P, Luciani A, Novello S, Scartozzi M, Emens LA, Solinas C. Petrelli F, et al. Among authors: luciani a. Breast. 2023 Feb;67:8-13. doi: 10.1016/j.breast.2022.12.004. Epub 2022 Dec 15. Breast. 2023. PMID: 36549170 Free PMC article.
This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthracyclines with or without taxanes alone....
This NMA showed an OS benefit from the incorporation of capecitabine into classic anthracycline/taxane-based combinations compared to anthra …
29 results